CONTENIDO

  • Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1

    Roger Badia, Eva Riveira-Muñoz, Bonaventura Clotet, José A. Esté and Ester Ballana

    IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain

    Roger Badia, Eva Riveira-Muñoz, Bonaventura Clotet, José A. Esté, and Ester Ballana. Gene editing using a zinc-finger nuclease mimicking the CCR532 mutation induces resistance to CCR5-using HIV-1. J. Antimicrob. Chemother. 2014 : dku072v1-dku072

  • p21 regulates the HIV-1 restriction factor SAMHD1

    Eduardo Paulsa,1, Alba Ruiza,1, Eva Riveira-Muñoza, Marc Permanyera, Roger Badiaa, Bonaventura Cloteta, Oliver T. Kepplerb, Ester Ballanaa, and Jose A. Estea,2

    aInstitute for AIDS Research IrsiCaixa and AIDS Unit, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, 08916, Spain; and b Institute of Medical Virology, University of Frankfurt, Frankfurt, Germany

     

    PNAS 2014 ; published ahead of print March 7, 2014 See

    Eduardo Pauls, Alba Ruiz, Eva Riveira-Muñoz, Marc Permanyer, Roger Badia, Bonaventura Clotet, Oliver T. Keppler, Ester Ballana, and Jose A. Este PNAS 2014

  • DIFFERENTIAL ESCAPE PATTERNS WITHIN THE DOMINANT HLA-B*57:03-RESTRICTED HIV GAG EPITOPE REFLECT DISTINCT CLADE-SPECIFIC FUNCTIONAL CONSTRAINTS

    R. P. Payne1, S. Branch2, H. Kløverpris1,3, P. C. Matthews1, C. K. Koofhethile1, T. Strong1, E. Adland1, E. Leitman1, J. Frater4,5, T. Ndung'u6, E. Hunter7,8, R. Haubrich9, B. Mothe10, A. Edwards11, L. Riddell12, F. Chen13, P. R. Harrigan14, Z. L. Brumme14,15, S. Mallal16,17, M. John16,17, J. P. Jooste18, R. Shapiro19, S. G. Deeks20, B. D. Walker6,21, C. Brander10,22, C. Landis2, J. M. Carlson23, J. G. Prado10 and P. J. R. Goulder1,6

     

    1Department of Paediatrics, University of Oxford, Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK
    2Ladymeade Reference Unit, Queen Elizabeth Hospital, Bridgetown, Barbados
    3K-RITH, University of Kwa-Zulu Natal, Duran, South Africa
    4Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
    5Oxford NIHR Biomedical Research Centre, Oxford, UK
    6HIV Pathogenesis Program, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, 4013, South Africa
    7Emory Vaccine Center, Yerkes National Primate Research Centre, Emory University, Atlanta, Georgia, USA
    8Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
    9Antiviral Research Center, University of California San Diego, San Diego, California, USA
    10IrsiCaixa AIDS Research Institute - HIVCAT, Hospital Germans Trias i Pujol, Badalona, Spain
    11Oxford Department of Genitourinary Medicine, The Churchill Hospital, Oxford, UK
    12Department of Genitourinary Medicine, Northamptonshire Healthcare National Health Service Trust, Northampton General Hospital, Cliftonville, Northampton, UK
    13Department of Sexual Health, Royal Berkshire Hospital, Reading, UK
    14British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
    15Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada
    16Centre for Clinical Immunology and Biomedical Statistics, Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
    17Department of Clinical Immunology, Royal Perth Hospital, Perth, Western Australia, Australia
    18Paediatric Department, Kimberley Hospital, Northern Cape, South Africa
    19Department of Immunology and Infectious Diseases, Harvard School of Public Health, 110 Francis Street, Boston, MA 02215, USA
    20Dept of Medicine, University of California, San Francisco, CA, USA
    21Ragon Institute of MGH, MIT, and Harvard, AIDS Research Center, Rm. 5212D, 149 13th Street, Charlestown, MA 02129, USA
    22Institució Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain
    23Microsoft Research, eScience Group, Los Angeles CA, USA

    J Virol. 2014 Feb 5. [Epub ahead of print]

  • IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients

    Franco, Sandraa; Aparicio, Estera; Parera, Marionaa; Clotet, Bonaventuraa,b; Tural, Cristinab; Martinez, Miguel Angela

     

    a Fundació IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona b Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

    doi: 10.1097/QAD.0000000000000052